Studies reporting results of long-term follow-up of primary RCTs were excluded. Double-blind RCTs of vitamin D 3, vitamin D 2, or 25-hydroxyvitamin D (25D) supplementation for any duration, with a placebo or low-dose vitamin D control, were eligible if they had been approved by a research ethics committee, and if ARI incidence was collected prospectively and prespecified as an efficacy outcome. Advancing women in science, medicine and global healthįor this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the registry for studies listed from database inception to May 1, 2020.The Lancet Regional Health – Western Pacific.The Lancet Gastroenterology & Hepatology.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |